MA38287B1 - Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer - Google Patents

Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer

Info

Publication number
MA38287B1
MA38287B1 MA38287A MA38287A MA38287B1 MA 38287 B1 MA38287 B1 MA 38287B1 MA 38287 A MA38287 A MA 38287A MA 38287 A MA38287 A MA 38287A MA 38287 B1 MA38287 B1 MA 38287B1
Authority
MA
Morocco
Prior art keywords
treatment
cancer
prevention
new
aminopyrazine derivatives
Prior art date
Application number
MA38287A
Other languages
English (en)
Other versions
MA38287A1 (fr
Inventor
Bernard Christophe Barlaam
David Berry
Benedicte Delouvrie
Craig Steven Harris
Der Brempt Christine Marie Paul Lambert-Van
Gilles Ouvry
Gary Patrick Reid
Gary Peter Tomkinson
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd filed Critical Astrazeneca Ab
Publication of MA38287A1 publication Critical patent/MA38287A1/fr
Publication of MA38287B1 publication Critical patent/MA38287B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

)la présente invention concerne des composés de formule (i) (formule (i)) ou ses sels pharmaceutiquement acceptables, où r1 et r2 ont les mêmes significations que celles données dans la description; leurs procédés de préparation, des compositions pharmaceutiques les contenant et leur utilisation dans le traitement de troubles cellulaires prolifératifs.
MA38287A 2013-01-23 2014-01-22 Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer MA38287B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305078 2013-01-23
PCT/GB2014/050163 WO2014114928A1 (fr) 2013-01-23 2014-01-22 Composés chimiques

Publications (2)

Publication Number Publication Date
MA38287A1 MA38287A1 (fr) 2018-01-31
MA38287B1 true MA38287B1 (fr) 2018-08-31

Family

ID=47623992

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38287A MA38287B1 (fr) 2013-01-23 2014-01-22 Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer

Country Status (27)

Country Link
US (2) US9156831B2 (fr)
EP (1) EP2948447B1 (fr)
JP (1) JP6307096B2 (fr)
KR (1) KR102202516B1 (fr)
CN (1) CN104936953B (fr)
AP (1) AP2015008604A0 (fr)
AR (1) AR094553A1 (fr)
AU (1) AU2014208964B2 (fr)
BR (1) BR112015017331B1 (fr)
CA (1) CA2897279C (fr)
CL (1) CL2015002027A1 (fr)
CR (1) CR20150367A (fr)
DO (1) DOP2015000170A (fr)
ES (1) ES2608395T3 (fr)
HK (1) HK1214592A1 (fr)
IL (1) IL239890A0 (fr)
MA (1) MA38287B1 (fr)
MX (1) MX361136B (fr)
NI (1) NI201500096A (fr)
PE (1) PE20151979A1 (fr)
PH (1) PH12015501584A1 (fr)
RU (1) RU2644769C2 (fr)
SG (1) SG11201505631PA (fr)
TN (1) TN2015000313A1 (fr)
TW (1) TWI606047B (fr)
UY (1) UY35275A (fr)
WO (1) WO2014114928A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146591A1 (fr) * 2015-03-16 2016-09-22 Astrazeneca Ab Traitement de combinaison
TW201726140A (zh) 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN107137405A (zh) * 2017-04-14 2017-09-08 黄德莲 一种治疗肾炎的药物组合物
CN110317190A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑-羧酸酯类衍生物在医药领域的应用
CA3118493A1 (fr) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion de til utilisant des inhibiteurs de la voie akt
BR112021008675A2 (pt) 2018-11-05 2021-08-10 Syngenta Participations Ag compostos de azole-amida pesticidamente ativos
JP2022523434A (ja) 2019-03-08 2022-04-22 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に活性なアゾール－アミド化合物
JP7549601B2 (ja) 2019-03-20 2024-09-11 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物活性アゾールアミド化合物
EP3941914A1 (fr) 2019-03-22 2022-01-26 Syngenta Crop Protection AG Dérivés de n-[1-(5-bromo-2-pyrimidin-2-yl-1,2,4-triazol-3-yl)éthyl]-2-cyclopropyl-6-(trifluorométhyl)pyridine-4-carboxamide et composés apparentés servant d'insecticides
BR112022021089A2 (pt) 2020-04-24 2022-12-06 Astrazeneca Ab Formulações farmacêuticas

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7112373A (fr) 1970-09-25 1972-03-28
US4256887A (en) 1978-04-06 1981-03-17 Merck & Co., Inc. 1,2,4-Triazoles and a method for their preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JP3028168B2 (ja) 1993-03-29 2000-04-04 住化ファインケム株式会社 ベンゼンスルホンアミド誘導体の製造方法
US5656416A (en) 1994-12-22 1997-08-12 Eastman Kodak Company Photographic processing composition and method using organic catalyst for peroxide bleaching agent
NZ301265A (en) 1995-02-02 1998-12-23 Smithkline Beecham Plc Indole derivatives as 5ht receptor antagonists, preparation and pharmaceutical compositions thereof
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
EP0915877A1 (fr) 1996-07-25 1999-05-19 MERCK SHARP & DOHME LTD. DERIVES DE TRIAZOLO-PYRIDAZINE SUBSTITUES UTILISES COMME AGONISTES INVERSES DU SOUS-TYPE DE RECEPTEUR GABA A?$g(a)5
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
EP1303507A1 (fr) 2000-07-19 2003-04-23 F. Hoffmann-La Roche Ag Derives de pyrimidine
PT1446387E (pt) 2001-11-21 2009-12-21 Pharmacia & Upjohn Co Llc Derivados de aril-1,4-pirazina substituídos
US7012077B2 (en) 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
WO2003062224A1 (fr) 2002-01-17 2003-07-31 Eli Lilly And Company Composes azacycliques en tant que modulateurs de recepteurs d'acetylcholine
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
CA2484209C (fr) 2002-05-03 2013-06-11 Exelixis, Inc. Modulateurs de proteine kinase et procedes d'utilisation
GB0306097D0 (en) 2003-03-15 2003-04-23 Elam T Ltd Electroluminescent complexes
WO2004084813A2 (fr) 2003-03-21 2004-10-07 Smithkline Beecham Corporation Composes chimiques
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DK1704145T3 (da) 2004-01-12 2012-09-24 Ym Biosciences Australia Pty Selektive kinaseinhibitorer
ATE458730T1 (de) 2004-04-13 2010-03-15 Icagen Inc Polycyclische pyrazine als kaliumionenkanal- modulatoren
JP2006028056A (ja) 2004-07-14 2006-02-02 Agro Kanesho Co Ltd ピリミジン誘導体及びこれを含む有害生物防除剤
MX2007001029A (es) 2004-07-26 2007-04-12 Lilly Co Eli Agentes del receptor de histamina h3, preparacion y usos terapeuticos.
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
TW200626592A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101242834A (zh) 2004-12-15 2008-08-13 默克公司 Akt活性抑制剂
WO2006084030A2 (fr) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Petites molecules inhibitrices du hsp90
MX2007015578A (es) 2005-06-10 2008-03-06 Merck & Co Inc Inhibidores de la actividad akt.
WO2007096764A2 (fr) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Dérivés d'hétéroaryles bicycliques en tant que modulateurs des récepteurs cannabinoïdes
DE602007004092D1 (de) 2006-03-22 2010-02-11 Vertex Pharma C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
WO2007147874A1 (fr) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Dérivés de pyridine et de pyrazine utilisés en tant qu'inhibiteurs de la kinase mnk
CA2656202C (fr) 2006-06-30 2018-01-16 Sloan-Kettering Institute For Cancer Research Traitement de maladies neurodegeneratives par l'inhibition de hsp90
CL2007002123A1 (es) 2006-07-21 2008-06-13 Irm Llc Compuestos derivados de heteroaril-1h-pirazol, utiles como moduladores del desarrollo y funcion de los linfocitos b.
CA2659851C (fr) 2006-08-23 2014-02-25 Kudos Pharmaceuticals Limited Derives de la 2-methylmorpholine pyrido-, pyrazo- et pyrimido-pyrimidine en tant qu'inhibiteurs de mtor
US8119671B2 (en) 2007-03-07 2012-02-21 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and pest control agent
KR20100053556A (ko) 2007-08-14 2010-05-20 바이엘 쉐링 파마 악티엔게젤샤프트 융합된 바이시클릭 피리미딘
WO2009024825A1 (fr) 2007-08-21 2009-02-26 Astrazeneca Ab Dérivés de 2-pyrazinylbenzimidazole en tant qu'inhibiteurs des récepteurs tyrosine kinase
NZ585261A (en) 2007-10-11 2011-10-28 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
ATE523508T1 (de) 2007-10-25 2011-09-15 Astrazeneca Ab Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate
WO2009072621A1 (fr) 2007-12-07 2009-06-11 Nissan Chemical Industries, Ltd. Composé dihydroazole substitué et agent antiparasitaire
CN101939319A (zh) 2007-12-20 2011-01-05 诺瓦提斯公司 联噻唑衍生物、它们的制备方法以及它们作为药物的用途
US20110150833A1 (en) 2007-12-21 2011-06-23 The Scripps Research Institute Benzopyrans and analogs as rho kinase inhibitors
WO2009157880A1 (fr) 2008-06-27 2009-12-30 S*Bio Pte Ltd Purines substituées par la pyrazine
EA201100426A1 (ru) 2008-09-02 2011-10-31 Новартис Аг Бициклические ингибиторы киназы
JP2010083883A (ja) 2008-09-08 2010-04-15 Nissan Chem Ind Ltd イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
JP2010063863A (ja) 2008-09-11 2010-03-25 Mugen:Kk ヘッドのフェース部背面に音響振動の異なるパイプまたは平板を複数設けた打点位置表示型ゴルフ練習用クラブとその製法
CN101676271B (zh) 2008-09-17 2011-12-14 山东轩竹医药科技有限公司 含有不饱和杂环胺的四环素衍生物
RU2011123647A (ru) 2008-11-10 2012-12-20 Вертекс Фармасьютикалз Инкорпорейтед Соединения, полезные в качестве ингибиторов atr киназы
PE20110906A1 (es) * 2008-11-14 2011-12-21 Bayer Ip Gmbh Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif
SI2376485T1 (en) 2008-12-19 2018-04-30 Vertex Pharmaceuticals Incorporated PIRAZINE DERIVATIVES USE AS ATR KINASE INHIBITORS
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
WO2010086613A1 (fr) 2009-01-30 2010-08-05 Betagenon Ab Composés utiles en tant qu'inhibiteurs tel que ampk
JP5667085B2 (ja) * 2009-02-13 2015-02-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔインヒビターとしての融合されたピリミジン
CN102317291B (zh) 2009-02-13 2015-02-11 拜耳知识产权有限责任公司 稠合嘧啶
CA2754523A1 (fr) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3,3.1]nonanes
GB0909441D0 (en) 2009-06-02 2009-07-15 Univ Sheffield Novel indole derivatives
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8354403B2 (en) 2009-08-27 2013-01-15 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
TW201125867A (en) 2009-10-20 2011-08-01 Cellzome Ltd Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
EP2338888A1 (fr) 2009-12-24 2011-06-29 Almirall, S.A. Dérivés d'imidazopyridine en tant qu'inhibiteurs JAK
WO2011089400A1 (fr) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibiteurs de la pi3 kinase
MX2012008550A (es) 2010-02-05 2012-09-07 Merck Patent Gmbh Derivados de hetaril-[1, 8]naftiridina.
JP2011178673A (ja) 2010-02-26 2011-09-15 Nissan Chem Ind Ltd 非農園芸害虫の防除方法
MX355038B (es) 2010-03-30 2018-03-28 Verseon Corp Compuestos aromáticos multisustituidos como inhibidores de trombina.
EP2560488B1 (fr) 2010-04-23 2015-10-28 Cytokinetics, Inc. Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation
MX2012013081A (es) 2010-05-12 2013-05-09 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
CA2812091C (fr) * 2010-09-14 2020-03-24 Exelixis, Inc. Inhibiteur de pi3k-delta et procedes d'utilisation et de fabrication correspondants
BR112013005855A2 (pt) * 2010-09-16 2016-05-17 Hutchison Medipharma Ltd heteroarilas fundidas e seus usos
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CN102718745A (zh) * 2011-03-30 2012-10-10 中国科学院上海药物研究所 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CA2837312A1 (fr) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Modulateurs allosteriques du recepteur 5 du glutamate methabotropique et methodes d'utilisation associees
WO2013049591A2 (fr) 2011-09-29 2013-04-04 Verseon Corporation Composés doublement inhibiteurs et procédés d'utilisation de ceux-ci
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法

Also Published As

Publication number Publication date
JP2016508484A (ja) 2016-03-22
PH12015501584A1 (en) 2015-10-05
BR112015017331A8 (pt) 2019-11-12
TW201522329A (zh) 2015-06-16
JP6307096B2 (ja) 2018-04-04
US20160137634A1 (en) 2016-05-19
UY35275A (es) 2014-07-31
PE20151979A1 (es) 2016-01-15
CL2015002027A1 (es) 2015-11-13
MX361136B (es) 2018-11-28
BR112015017331B1 (pt) 2022-01-11
CN104936953A (zh) 2015-09-23
ES2608395T3 (es) 2017-04-10
DOP2015000170A (es) 2015-08-16
NI201500096A (es) 2016-02-16
RU2644769C2 (ru) 2018-02-14
CR20150367A (es) 2015-10-20
KR20150109385A (ko) 2015-10-01
MX2015009465A (es) 2015-09-28
AP2015008604A0 (en) 2015-07-31
RU2015132370A (ru) 2017-03-02
AR094553A1 (es) 2015-08-12
TWI606047B (zh) 2017-11-21
US20140206700A1 (en) 2014-07-24
BR112015017331A2 (pt) 2017-07-11
IL239890A0 (en) 2015-08-31
EP2948447A1 (fr) 2015-12-02
US9657008B2 (en) 2017-05-23
TN2015000313A1 (en) 2017-01-03
KR102202516B1 (ko) 2021-01-12
EP2948447B1 (fr) 2016-09-21
US9156831B2 (en) 2015-10-13
AU2014208964A1 (en) 2015-08-06
MA38287A1 (fr) 2018-01-31
SG11201505631PA (en) 2015-08-28
CA2897279A1 (fr) 2014-07-31
WO2014114928A1 (fr) 2014-07-31
AU2014208964B2 (en) 2016-09-01
HK1214592A1 (zh) 2016-07-29
CA2897279C (fr) 2020-12-29
CN104936953B (zh) 2017-03-08

Similar Documents

Publication Publication Date Title
MA38287A1 (fr) Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
MA38138A1 (fr) Dérivés inédits de quinolone
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA38099A1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
EA201590748A1 (ru) Противовирусные соединения против rsv
MA38999A1 (fr) Nouveaux composés hétérocycliques
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
EA201291300A1 (ru) Производные нафт-2-илуксусной кислоты для лечения спида
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA38803A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent